Hepatitis E is an important public health problem in many developing countries. The disease generally affects young adults. The causative agent of Hepatitis E, Hepatitis E virus (HEV), is a single-stranded positive-sense RNA virus without an envelope (1). HEV is generally transmitted by fecal-oral route. The genomic RNA of HEV is about 7.5 kb with three open reading frames (ORFs). ORF1 is predicted to encode viral nonstructural proteins, ORF2 encodes the putative capsid protein, and ORF3 encodes a cytoskeleton-associated phosphoprotein (2, 3). HEV was originally classified as a calicivirus, but recent data showed that HEV does not share some common important features with caliciviruses. It was recently declassified from the Caliciviridae family and remains unclassified (4).

Iran is a part of developing Asia with high incidence and prevalence of type A hepatitis, therefore it is expected to have incidences of Hepatitis E. Unfortunately, there has been no documented study to explain the statistical characteristics of this infection in the general population. We studied the level of seropositivity of a group of blood donors in a cross-sectional study in Kerman during 2007-2008 (5).

Among the 400 plasma samples analyzed, a total of 31 were found to be positive for anti-HEV IgG, corresponding to a prevalence rate of 7.7%, however, no significant difference was observed (P = 0.45).

No data on type of job activities of the donors were available, but it was interested to know whether some of them had occupations involved in animal contacts. Another possibility is that sanitation may play a more prominent role in urban than rural areas. None of the positive donors had recently traveled to the endemic regions, but they might have traveled outside Kerman long time ago and...
been exposed to HEV. Thus, it is not possible to conclude that HEV was acquired locally. Hepatitis E is observed in young adults in our endemic regions while in industrialized countries, HEV seems to be more frequent in older adults. To characterize this epidemiological feature of HEV infection in Kerman, the data of four different age groups were analyzed: 20-30, 30-40, 40-50 and 50-60 years old of age (Figure1 and 2). Figure1 shows the prevalence of anti-HEV positivity in different age groups, and the Fig. 2 shows the frequency of this distribution. Table 1 also shows Age-specific prevalence of hepatitis E virus (HEV) IgG antibodies in subjects from rural and urban area. Thus, the probability of exposure to HEV seems to increase with age. The overall prevalence of anti-HEV antibodies among our blood donors was 7.4%, which is generally higher than figures reported from developed countries (0.4% to 3.9%) (6, 7), and lower than those from other countries of the Eastern Mediterranean Region (52%). The obtained value is higher than those obtained in Israel (Jews 2.81% and Arabs 1.81%) and Ankara, Turkey (3.8%), but less than studied values of Iraqis-Kurdish refugees (14.8%), blood donors in Saudi Arabia (16.4%) and general population in Pakistan (17.5%). The ratio was more or less similar to the value obtained in a group of healthy blood donors in Riyadh (8.37%) (5).

There are no published study regarding the prevalence and incidence of HEV infection in Kerman. We studied anti-HEV seropositivity in a group of healthy blood donors in Kerman and noticed a prevalence of more than 7.4%, which correlates with the prevalence of endemic areas.

Our method of screening detected anti HEV IgG, which is a routine test to detect HEV infection. No significant difference was observed in seropositivity between males and females. The lowest rate of seropositivity was observed in less than 20-30 years, and a peak level in the 30-40 years of age followed by a decline in the higher ages. Our data correlates to most other studies. Since the HEV excretion is not usual, transmission rate and prevalence of the infection is low.

According to the results of our study we conclude that Kerman is an endemic area of type E hepatitis and we suggest further investigation since there will be higher incidence of the infection in general population particularly in rural areas.

Determination of anti-HEV in healthy blood donors is not routine now. The available kits to detect anti-HEV IgM have some limitations. Although the HEV-specific polymerase chain reaction (PCR) test is sensitive and specific, screening of the blood using PCR would not be cost-effective. In conclusion, seroprevalence of the HEV among blood donors in our study in Kerman is high, but we cannot recommend screening of all blood donors for HEV until more data becomes available and further knowledge about the mode of transmission of HEV becomes available.

References